dc 1

DC1 can be used to synthesize antibody-drug conjugates targeted to the treatment of cancer, is an ADC cytotoxin, similar to the small groove-binding DNA alkylating agent CC-1065.

DC1 is an ADC cytotoxin, similar to the small groove-binding DNA alkylating agent CC-1065. DC1 can be used to synthesize antibody-drug conjugates targeted to the treatment of cancer. DC1Sme is a DC1 derivative with IC50 values of Ramos, Namalwa, HL60 / s

Dc1a, a toxin isolated from the desert bush spider Diguetia canities [1], potently facilitates the opening of the German cockroach Na v channel (BgNa v 1).

AntibioticDC 102 is a novel glycosylated pyrrole (1,4) benzodiazepine-class antibiotic targeting Bacillus subtilis, with a minimum inhibitory concentration (MIC) of 42 μg/mL. The lethal dose 50 (LD50) in mice, when administered intraperitoneally (i.p), is 1.5 mg/mL.

TCMDC-135051 is a potent and selective PfCLK3 protein kinase inhibitor demonstrating significant antiparasiticidal activity (EC50=320 nM) while exhibiting minimal off-target toxicity. It effectively hinders the transition from trophozoite to schizont, impairs transcription, and diminishes transmission to the mosquito vector.

Rabacfosadine (GS-9219) is a novel dual pre-drug of the acyclic nucleotide phosphonate PMEG to tumor lymphocytes for the study of lymphoma.

Permethrin (NRDC-143) is a pyrethroid insecticide commonly used in the treatment of LICE INFESTATIONS and SCABIES.

ADC-13 ((5R,6S)-4-Nitrobenzyl 6-((R)-1-hydroxyethyl)-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate) is a p-nitrobenzyl ester β-lactam derivative, functioning as an intermediate in carbapenem antibiotic synthesis.

Acid-C1-PEG5-Boc, a PEG-based PROTAC linker, is utilized in PROTAC synthesis.

DC10SMe is a DNA alkylating agent that can be used in the synthesis of antibody-drug conjugates (ADC). The IC50 of DC10SMe for Ramos, Namalwa and HL60 / s cancer cells were 15 pM, 12 pM and 12 pM, respectively.

TCMDC-135051 TFA is a highly selective and potent inhibitor of protein kinase PfCLK3.

YL-5092 is a YTHDC1 inhibitor (IC50=7.4 nM, KD=29.6 nM) that suppresses cancer cell proliferation, induces G0/G1 phase arrest and apoptosis, and can be used in studies of acute myeloid leukemia (AML).

DC-159a, an 8-methoxy fluoroquinolone, possesses broad-spectrum antibacterial activity, with a particular efficacy against Gram-positive pathogens. The MIC90 values for DC-159a are 0.5 μg/mL against Streptococcus anginosus group, 4 μg/mL against Clostridium difficile, and 2 μg/mL against Bacteroides fragilis.

DDC18-8A is an amphiphilic dendritic polymer known for its potent antimicrobial and antibiofilm properties.

CDC14A/B-IN-1 (Compound 15) is an orally bioavailable inhibitor of CDC14A/B phosphatases, exhibiting inhibition constants (Ki) of 57.4 nM for CDC14A and 90.0 nM for CDC14B.

DC-174 is an orally active snake venom metalloproteinase (SVMP) inhibitor with broad-spectrum activity against various snake venom SVMPs. It binds directly to the active site of SVMP through a zinc-binding group, inhibiting its enzymatic activity and procoagulant toxicity. DC-174 significantly prolongs the survival time of mice under snake venom attack and is applicable for researching emergency treatment of snakebites.

LDC1267 is a excellently specific TAM(Tyro3, Axl and Mer) kinase inhibitor, for Mer( IC50<5 nM), Tyro3(IC50=8 nM), and Axl(IC50=29 nM).

Rabacfosadine succinate is the acyclic nucleoside phosphonate PMEG double prodrug.

CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4 nM, 2.4 nM, and 15.7 nM, respectively.

SB-282241 is a bioactive chemical.

Compound C108 is an inhibitor of GTPase-activating protein SH3 domain-binding protein 2 (G3BP2). Compound C108 can be used in studies about breast tumors and esophageal squamous cell carcinoma.

PF-06761281 (Compound 4a) is a potent and partially selective sodium-coupled citrate transporter protein (NaCT/SLC13A5) inhibitor with IC50 values of 0.51, 13.2, and 14.1 µM for NaCT, NaDC, and NaDC, respectively, and has the advantage of being orally active, reducing hepatic and renal uptake of citrate and plasma glucose concentration for metabolic diseases.

TCMDC-125457 can effectively induce calcium redistribution, but has little effect on inhibiting heme crystallization. When TCMDC-125457 is combined with artesunate, it can effectively treat tightly synchronized artemisinin-resistant ring-stage parasites.

TCMDC-125431 is a novel inhibitor of Plasmodium calcium kinetics with minimal inhibition of haemoglobin crystals.